Pharmaceutical News

RSS

Scientists report on development of new malaria drug

Scientists are reporting development of a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge and may fight off the disease with one dose, instead of the multiple doses that people often fail to take.

18 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Study examines long-term affect of multivitamins on major chronic diseases

A daily multivitamin can help a man reduce his risk of cancer, according to new research from Brigham and Women's Hospital.

18 Oct 2012

Trial results of first new TB vaccine candidate in 90 years expected next year

"Researchers will find out early next year whether the first new vaccine against tuberculosis [TB] for 90 years protects against a disease that was once neglected but is now resurgent worldwide," Financial Times reports.

18 Oct 2012

NPR examines efforts to eradicate polio in Nigeria

NPR's "Shots" blog reports on efforts to eradicate polio in Nigeria. "[N]orthern Nigeria is the only place in the world where polio cases are increasing," the blog writes, noting, "As of Sept. 1, it had recorded 90 polio cases in 2012 -- or nearly three times as many as in the same period last year."

18 Oct 2012

Additional drugs linked to meningitis outbreak

Food and Drug Administration officials said Monday that more people may be at risk as a result of contaminated drugs made by a Massachusetts compounding pharmacy.

17 Oct 2012

Prescription pain medication abuse on the rise among current generation of adolescents

A new study by the University of Colorado Denver reveals that today's adolescents are abusing prescription pain medications like vicodin, valium and oxycontin at a rate 40 percent higher than previous generations.

17 Oct 2012

FDA accepts A.P. Pharma’s resubmission of NDA for APF530

A.P. Pharma, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of its New Drug Application (NDA) for APF530.

17 Oct 2012

Novel drug increases survival in animal models exposed to high-dose radiation

A novel drug that mimics a naturally occurring molecule found in coffee and blueberries has been developed to treat radiation exposure. Charles R. Yates, Pharm.D., Ph.D., and colleagues Duane Miller, Ph.D., and Waleed Gaber, Ph.D., from the University of Tennessee Health Science Center and Baylor College of Medicine, show that application of this drug, starting 24 hours after radiation exposure, increases survival in animal models by three-fold compared to placebo.

17 Oct 2012

Benzocaine oral strip immediately relieves pain from burns

A dissolvable oral strip has been developed to immediately relieve pain from burns caused by ingestion of hot foods and liquids, such as coffee, pizza, and soup. This research is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Chicago, Ill., on Oct. 14 - 18.

17 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Positive results from PROLOR's Rpeg preclinical toxicology study

PROLOR Biotech, Inc. today announced positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology.

17 Oct 2012

Offering methadone treatment to drug users significantly reduces HIV infection, transmission risk, study shows

Offering methadone treatment to people who use injection drugs "substantially reduces the risk that they will get HIV or give it to anyone else," according to a BMJ study published this month that pools data from studies done in nine countries, the New York Times reports.

17 Oct 2012

Intensive treatment with high doses of statin drugs shows promise for dyslipidemia

A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.

16 Oct 2012

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

For decades, patients with Parkinson's disease (PD) have had the same experience. Their hands start to shake uncontrollably, their limbs become rigid and they lose their balance. Years before those movement problems set in, many begin struggling with fainting, incontinence, sexual dysfunction, anxiety and depression. Many patients are still treated with a 42-year-old drug called L-DOPA, which temporarily staves off symptoms but can itself cause heart arrhythmias, stomach bleeding and hallucinations.

16 Oct 2012

Mother rats respond much differently to cocaine than non-mothers

Mother rats respond much differently to cocaine than female rats that have never given birth, according to new University of Michigan research that looks at both behavior and brain chemistry.

16 Oct 2012

Thymic stromal lymphopoietin molecule makes mice resistant to skin cancer

A molecule involved in asthma and allergies has now been shown to make mice resistant to skin cancer, according to scientists at Washington University School of Medicine in St. Louis.

16 Oct 2012

Current status, challenges and opportunities of pulmonary vaccine delivery

In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track.

16 Oct 2012

VeriStrat identifies NSCLC patients likely to respond to erlotinib

A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.

16 Oct 2012

FOS prebiotic could replace intravenous feeding in pediatric patients with intestinal failure

Adding the right prebiotic to the diets of pediatric patients with intestinal failure could replace intravenous feeding, says a new University of Illinois study.

16 Oct 2012